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Abstract The sarco(endo)plasmic reticulum Ca2+ ATPase
(SERCA) type 1 and 2 genes are alternatively spliced at their
3P end. We hypothesized that similar mechanism may occur for
SERCA 3. Two spliced variants were identified by RNase
protection analysis. We then isolated and sequenced the 3P end
portion of the mouse SERCA 3 gene, and confirmed the presence
of an alternative mRNA transcript by sequencing a cDNA
fragment obtained by RT-PCR. Tissue distribution of the
alternatively spliced mRNAs was studied by RT-PCR: SERCA
3b was the only isoform expressed in endothelial cells from aorta
and heart and also was the major isoform in lung and kidney
whereas SERCA 3a and 3b were coexpressed in trachea,
intestine, thymus, spleen, and fetal liver.
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1. Introduction
The sarco(endo)plasmic reticulum Ca2 ATPases (SERCA)
play a crucial role in Ca2 homeostasis and signalling by
mediating re-uptake of Ca2 from the cytosol into intracellu-
lar Ca2 stores. Several SERCA isoforms, encoded by three
di¡erent genes, i.e. SERCA 1, SERCA 2 and SERCA 3 have
been identi¢ed ([1,2] for reviews). These pumps have a very
high degree of identity but a di¡erent pattern of expression.
SERCA 1 is exclusively expressed in fast skeletal muscles, and
gives rise to two alternatively spliced transcripts : SERCA 1a
in adult and SERCA 1b in neonatal muscles. The last eight C-
terminal amino acids of SERCA 1b are replaced by a single
glycine residue in SERCA 1a [3,4]. The SERCA 2 gene also
encodes two alternatively spliced transcripts : SERCA 2a is
expressed in heart, slow skeletal and some smooth muscles
in the adult, and also in embryonic skeletal muscles, whereas
SERCA 2b is a housekeeping isoform present in all cell types
[5^7]. The last four C-terminal amino acids of SERCA 2a are
replaced in SERCA 2b by 49 residues [8^10]. In the adult,
SERCA 3 is expressed in a broad variety of tissues [11] but
in speci¢c cell types such as endothelial cells, epithelial cells
from trachea, spleen, lung, pancreas, stomach, salivary glands,
adrenal gland, thyroid, thymic cortex, cells of the intestinal
crypt, and purkinje cells in cerebellum [7,12^14]. SERCA 3 is
also present in the hemopoietic cell lineage and platelets, var-
ious lymphoid cell lines and mast cells [15,16]. This isoform is
always coexpressed with SERCA 2b. Furthermore, the se-
quences of two mouse SERCA 3 cDNAs [17] and of the 3P
end portion of the human SERCA 3 gene [13] were recently
published. In human, two mRNA populations di¡ering by
their size in Northern blot were detected, suggesting alterna-
tive splicing but the 3P end sequence of the gene did not reveal
the existence of an alternative exon [13].
The purpose of this work was to test whether the SERCA 3
gene, like the two other SERCA genes, can give rise to several
mRNA transcripts by alternative splicing at its 3P end and to
study tissue distribution of the various transcripts.
2. Material and methods
2.1. Library screening and DNA sequencing
A 516 bp PstI fragment from the 3P untranslated region of the rat
SERCA 3 cDNA clone RK 8-13 [11], corresponding to nucleotides
(nt) 3277 to 3792, was used to screen a mouse genomic library
(129SVJ in Lambda Fix vector, Stratagene). The selected genomic
clones were subcloned into pBKS vector and digested with various
enzymes. A restriction map was constructed after hybridization of the
digested fragments with 32P-labeled oligonucleotides designed from
the rat SERCA 3 cDNA sequence [11]. Fragments were sequenced
in both directions (Sequenase kit, USB).
2.2. RNA isolation and RNase protection analysis
Total RNA from various rat and mouse tissues were isolated using
the guanidinium thiocyanate procedure (RNA instapure, Eurogentec).
RNase protection assay was performed on 20 Wg of total RNA from
adult rat aorta and trachea. A 807 bp SmaI-PstI fragment corre-
sponding to nt 2471^3277 of the rat cDNA RK 8^13 [11] was sub-
cloned into pBKS vector. The cRNA probe was prepared from the
BamHI linearized plasmid transcribed in vitro in the presence of T3
RNA polymerase (riboprobe system, Promega) and [K-32P]-CTP (800
Ci/mmol, NEN life Science). The full-length probe, puri¢ed on dena-
turing polyacrylamide gel, was hybridized to total RNA at 39‡C over-
night. Unreacted cRNA was digested by 50 U of RNase T1 at room
temperature for 30 min, following RPA II procedure (Ambion, Clin-
isciences). Yeast tRNA was used as a negative control. After diges-
tion, protected fragments were separated by electrophoresis and ex-
posed to X-ray ¢lm (Kodak, France).
2.3. Reverse transcription polymerase chain reaction (RT-PCR)
analysis
Five Wg of total RNA from mouse tissues were used for reverse
transcription using Ready-To-Go You-Prime ¢rst-Strand beads
(Pharmacia Biotech) and 0.2 Wg of random hexamers (Boehringer
Mannheim). Reaction was performed for 1 h at 37‡C. First-strand
DNA was ampli¢ed in presence of 2.5 U of AmpliTaq DNA polymer-
ase (Thermus aquaticus; Perkin Elmer) and 40 pmoles of each speci¢c
primer (Genset) for 105 s at 95‡C and 35 cycles of 15 s at 95‡C, 30 s at
64‡C, followed by 15 cycles of 15 s at 95‡C, 1 min at 64‡C and ¢nally
7 min at 72‡C. Controls without reverse transcription were performed
in each experiment. PCR products were separated on 12% polyacryl-
amide gel, stained with vistra green (Amersham Life Science) and
then electroblotted onto nylon membrane (Parablot NY plus; Ma-
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cherey-Nagel). Prehybridization was performed in 6Ustandard saline
citrate (1USSC contains 0.15 M sodium chloride and 0.015 M sodium
citrate), 0.1% ¢coll, 0.1% bovine serum albumin, 0.1% polyvinylpyr-
rolidone, 0.5% sodium dodecyl sulfate (SDS), 100 Wg/ml salmon sperm
DNA at 42‡C for 1 to 2 h. Hybridization was done in 6USSC, 0.5%
SDS and 100 Wg salmon sperm DNA at 39‡C overnight with an
internal oligonucleotide (nt 2925^2941) 32P-labeled using T4 kinase
and [Q32P]-ATP. After ¢nal washing for 1 h in 1USSC, 0.1% SDS
at 40‡C, the membrane was exposed to the phosphorimager screen
which was scan on a Storm (Molecular Dynamics).
3. Results and discussion
It has been clearly demonstrated that several mRNA iso-
forms are generated by alternative splicing at the 3P end of
SERCA 1 and SERCA 2 genes ([1,2] for reviews). Further-
more, in human platelets a novel SERCA 3 isoform recog-
nized by the PL/IM 430 antibody but di¡erent from SERCA 3
RK 8^13 [11] was also identi¢ed [18]. Thus, we hypothesized
that the SERCA 3 gene could also give rise to multiple iso-
forms by splicing at its 3P end. In a ¢rst approach, we
searched for the presence of multiple RNA populations by
RNase protection assay (RPA) using total RNA from tissues
expressing high level of SERCA 3, aorta and trachea. In aorta
SERCA 3 is expressed in endothelial cells whereas in trachea
it is present in epithelial cells [12]. When we used as a probe a
fragment of cDNA covering the 3P end of the coding sequence
and the beginning of the untranslated region, nt 2471 to 3277,
two mRNA populations were observed: the fully protected
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Fig. 1. RNase protection analysis of the expression of SERCA 3
mRNA variants. Total RNA rat from aorta and trachea as well as
yeast tRNA were hybridized to a cRNA probe generated from a
807 bp SmaI-PstI fragment corresponding to nt 2471^3277 of the
rat cDNA RK 8^13 [11]. The upper fragment corresponds to fully
protected probe SERCA 3a, and lower fragments to SERCA 3b.
Due to insertion of an additional exon in SERCA 3b, two major
fragments of approximately 500 bp and 300 bp are expected for
SERCA 3b (see below). The undigested probe, lane probe, is
slightly higher than the fully protected fragment due to insertion of
vector sequences. Positions of DNA markers (bp) are indicated.
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fragment corresponding to SERCA 3a was present in trachea
together with additional shorter fragments (Fig. 1). Only
shorter fragments were present in RNA from aorta. One of
these fragments, approximately 500 bp, was compatible with
the existence of a point of divergency near the end of the
coding region and thus with the presence of the two mRNA
sequences published by Tokuyama et al. [17].
To better characterize the mechanism of alternative splic-
ing, we have isolated and sequenced the 3P end portion of the
mouse SERCA 3 gene (Fig. 2). By comparing the genomic
sequence with that of the cDNAs [17], we could reconstruct
the SERCA 3 gene. We con¢rmed the sequence of SERCA 3b
cDNA by sequencing a PCR product obtained by reverse
transcription of cardiac RNA (not shown), where SERCA 3
is present in coronary arteries [12]. The additional 73 nucleo-
tides of SERCA 3b were located 387 nt downstream of the 3P
boundary of exon N31 and constitute the b speci¢c exon (b
sp). Exons were numbered by comparison with the human
SERCA 3 gene [13] and each of them had consensus exon/
intron boundaries. Addition of this exon modi¢ed the open
reading frame of exon N and led to usage of two di¡erent stop
codons (Fig. 2). This splicing mechanism leads to the gener-
ation of two proteins which di¡er in their C-terminal portion
by the substitution of the last six amino acids of SERCA 3a
by and extension of 45 amino acids in SERCA 3b. Based on
Northern blot detection of two mRNA populations in human
tissues (4.0 and 4.8 kb), the possible existence of alternatively
spliced isoforms was stressed out but the sequence of the
human gene 3P portion did not reveal the presence of an
alternative exon [13]. In fact, the SERCA 3b speci¢c exon
was located 349 bp downstream of the 3P boundary of exon
N31 [13,18]. Coding regions of the mouse genomic sequence
as well as the mouse cardiac cDNA sequence obtained by
PCR were absolutely identical to SERCA 3b cDNA sequence
previously published by Tokuyama et al. [17] but human and
mouse C-terminal regions were very di¡erent [13,18].
We then studied distribution of the alternative transcripts in
mouse tissues by RT-PCR using two sets of primers (see Fig.
2A for primer location). Using primers 21S and 22R, two
fragments were detected; their size was compatible with the
presence of SERCA 3b (303 bp) and SERCA 3a (229 bp)
(Fig. 3A). SERCA 3b was the only isoform expressed in aorta
and heart and the major one in lung and kidney whereas the
two isoforms were detected in all other tissues. No signal was
detected in C2C12 skeletal muscle or 10T1/2 ¢broblast cell
lines and in controls without reverse transcriptase (not
shown). The presence of SERCA 3b in aorta was in agree-
ment with the presence of only the short fragments in Fig. 1.
Similarly, in trachea, SERCA 3a was slightly more abundant
than SERCA 3b as shown by RPA and RT-PCR experiments
(Figs. 1 and 3). Note that in Fig. 1 speci¢c activity of the fully
protected fragment (3a) is two times higher than that of 3b,
whereas in Fig. 3 the same oligonucleotide is unable to detect
both isoforms with the same activity. We then used another
pair of primers, 21bS and 22R, to detect speci¢cally SERCA
3b or any other potential exon present between exon b sp and
exon N (Fig. 2A). These results con¢rmed that SERCA 3b
was expressed in each tissue (Fig. 3B). Furthermore only one
fragment was observed with these primers indicating that no
other coding sequence was detectable between exons b sp and
N.
Our data indicate that SERCA 3b is ubiquitously expressed
in tissues containing arterial endothelial cells (aorta, coronary
vessels from heart), epithelial (trachea, intestine, thymus, lung,
kidney) and lymphoid tissues (thymus, spleen) and that SER-
CA 3a is present in epithelial and lymphoid tissues but not in
endothelial cells. In human, SERCA 3a and 3b were both
detected in platelets and in a lymphoid cell line (Jurkat)
whereas only SERCA 3a was present in the epithelial-like
HeLa cell line [18]. One cannot exclude that the 3b isoform
we have seen in epithelial and lymphoid tissues corresponds to
endothelial cells of vessels. On the other hand, the presence of
only SERCA 3a in HeLa cells may be due to a shift from
expression of one isoform to the other during dedi¡erentiation
of cells in culture as we have shown in smooth muscle cells for
the SERCA 2 gene [19,20].
When expressed in COS cells, SERCA 3a has a lower af-
¢nity for Ca2, an enhanced sensitivity to vanadate and a
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Fig. 3. RT-PCR analysis of SERCA 3 spliced variants expression. A: Southern blot hybridization using an internal oligonucleotide of RT-PCR
products obtained with primers 21S and 22R. Two fragments of size compatible with SERCA 3b (303 bp) and SERCA 3a (229 bp) are de-
tected. B: RT-PCR products stained with vistra green. Primers used were 21bS and 22R. A single fragment located between 134 and 154 bp,
as expected for SERCA 3b (144 bp), was observed. This ¢gure is representative of at least three experiments performed on di¡erent RNA prep-
arations from di¡erent mice. Positions of DNA markers are indicated.
Fig. 2. Sequence and organization of the 3P end portion of the
mouse SERCA 3 gene. A: Sequence of the ¢fth last exons (upper
case) and introns (lower case). Nucleotides are numbered as referred
to Tokuyama et al. [17]. Amino acid sequence is presented beneath
the nucleotide sequence with the one-letter code. Two mRNA spe-
cies are generated by addition of a 73 bp additional exon, b sp, and
usage of two di¡erent stop codons (bold letters and stars). Primers
used for PCR are underlined: the upstream is 21S spanning from
exons N32 to N31, the middle 21bS, and the downstream 22R. B:
Schematic representation of the 3P end of the mouse SERCA 3 gene
and of the two mRNA species. Arrowheads indicate positions of
stop codons.
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higher optimum pH range than the other isoforms [21,22]. In
particular, SERCA 3a is less sensitive to Ca2 and more re-
sistant to peroxide than SERCA 2b with which it is coex-
pressed [21,23]. These unusual biochemical characteristics
and the prominence of Ca2 signalling in the cell types in
which SERCA 3 is expressed, suggest that it might have a
particular role in specialized Ca2-dependent functions. To
test the hypothesis that SERCA 3 has a particular role in
endothelial cells and can regulate the vascular tone, G. Shull’s
group has generated SERCA 3-de¢cient mice and analyzed
contraction and relaxation of aortic rings and Ca2 signalling
in endothelial cells [24]. Their results suggest that SERCA 3
plays an important role in mechanisms that mediate endothe-
lium-dependent relaxation of vascular smooth muscle. Our
data indicate that SERCA 3b is the only SERCA 3 isoform
expressed in endothelial cells. Thus, SERCA 3b should be
involved in synthesis or secretion of endothelial vasoactive
peptides but a speci¢c role for SERCA 3a remains to be
elucidated. We have previously shown that SERCA 3 is ex-
pressed at early embryonic stages in the rat, especially in
heart, dorsal aorta and liver [6]. However, the knock-out
data indicate that SERCA 3 is not absolutely necessary for
development since the SERCA 3-de¢cient mice are viable and
fertile. The role of SERCA 3 in embryos is not yet known.
Polarized expression of SERCAs was demonstrated in pancre-
atic acini and in submandibular salivary glands [14]. In pan-
creatic acini SERCA 2a is expressed at the luminal pole and
SERCA 2b at the basal pole and in the nuclear envelope. In
acinar and duct cells of submandibular salivary glands, SER-
CA 2b is present at the luminal pole and SERCA 3 at the
basal pole. Furthermore, in platelets, the 97 kDa-PL/IM 430
recognizable Ca2 pump, now identi¢ed as SERCA 3b [18], is
present only in structures associated with the cytoplasmic face
of plasma membranes whereas SERCA 3a and SERCA 2b are
in both peripheral and internal compartments [25].
In conclusion, we have shown that the SERCA 3 gene is
alternatively spliced using an exon skipping mechanism as
SERCA 1 gene. The two alternatively spliced variants are
coexpressed in many tissues but only SERCA 3b is present
in endothelial cells from aorta and heart.
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